78,922 Shares in Pfizer Inc. $PFE Bought by IMS Capital Management

IMS Capital Management bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 78,922 shares of the biopharmaceutical company’s stock, valued at approximately $1,913,000.

Other large investors also recently made changes to their positions in the company. Ballentine Partners LLC increased its holdings in shares of Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after acquiring an additional 458 shares during the last quarter. Wilsey Asset Management Inc. boosted its position in Pfizer by 4.6% during the second quarter. Wilsey Asset Management Inc. now owns 985,295 shares of the biopharmaceutical company’s stock worth $23,884,000 after purchasing an additional 43,566 shares during the period. BCS Wealth Management grew its holdings in Pfizer by 9.7% during the second quarter. BCS Wealth Management now owns 49,109 shares of the biopharmaceutical company’s stock valued at $1,190,000 after purchasing an additional 4,329 shares during the last quarter. Kagan Cocozza Asset Management raised its position in shares of Pfizer by 8.1% in the second quarter. Kagan Cocozza Asset Management now owns 17,086 shares of the biopharmaceutical company’s stock valued at $414,000 after purchasing an additional 1,273 shares during the period. Finally, Norden Group LLC lifted its stake in shares of Pfizer by 8.7% in the second quarter. Norden Group LLC now owns 35,455 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 2,828 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Trading Up 0.3%

Pfizer stock opened at $24.12 on Wednesday. The business has a 50 day moving average price of $24.60 and a two-hundred day moving average price of $24.18. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a market cap of $137.14 billion, a price-to-earnings ratio of 12.83, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.